Dr.Duvall introduces the casodex.
Click on image below to visit
AstraZeneca (AZ) has suffered another hard knock after it failed to win regulatory approval from the US food and drug administration (FDA) for the use of high-dose (150mg) for early stage prostate cancer, The company is already locked in a battle over patent protection for its ulcer drug Losec, which was, the world’s best-selling drug.
AstraZeneca has submitted a supplemental new drug application with the Food and Drug Administration for (bicalutamide) 150 mg monotherapy for the treatment of locally advanced, non-metastatic prostate cancer. In …
In data presented from the largest prostate cancer clinical trial program in the world, (R) (bicalutamide) 150 mg tablets (manufactured by AstraZeneca) was shown to significantly reduce (42%) the risk of disease progression in men with localized or locally advanced prostate cancer compared to placebo.